1h Free Analyst Time
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Angiotensin II receptor type 2 (AT2 receptor) is a protein encoded by the AGTR2 gene. AT2 receptor is highly expressed in the developing foetus, but its expression is very low in the cardiovascular system of the normal adult. Expression of the AT2 receptor can be modulated by pathological states associated with tissue remodeling or inflammation such as hypertension, atherosclerosis, and myocardial infarction. AT2 receptor plays an important role in vasodilatory role, and enhanced as a countervailing mechanism in cardiac hypertrophy, and in presence of vascular injury in hypertension and atherosclerosis. Speak directly to the analyst to clarify any post sales queries you may have.
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) pipeline Target constitutes close to 11 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase I, IND/CTA Filed and Preclinical stages are 1, 1, 2, 1 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Cardiovascular, Central Nervous System, Respiratory, Dermatology, Musculoskeletal Disorders, Gastrointestinal, Genito Urinary System And Sex Hormones, Infectious Disease, Metabolic Disorders and Oncology which include indications Idiopathic Pulmonary Fibrosis, Fibrosis, Neuropathic Pain (Neuralgia), Cardiomyopathy, Coronavirus Disease 2019 (COVID-19), Hyperlipidemia, Hypertension, Inflammatory Pain, Kidney Fibrosis, Liver Fibrosis, Myocardial Fibrosis, Pulmonary Arterial Hypertension, Pulmonary Hypertension, Skin Inflammation and Wounds.
The latest report Type 2 Angiotensin II Receptor - Drugs In Development, 2022, outlays comprehensive information on the Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2)
- The report reviews Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- Report Coverage
- Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Overview
- Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Companies Involved in Therapeutics Development
- Confo Therapeutics SA
- HK inno.N Corp
- MorphoSys AG
- Novopyxis Inc
- Shandong Danhong Pharmaceutical Co Ltd
- Vicore Pharma AB
- Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Drug Profiles
- (amlodipine besylate + valsartan) + atorvastatin calcium - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- C-106 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- CFTX-1554 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- MOR-107 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- NP-6A - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecule to Antagonize AGTR2 for Skin Inflammation and Inflammatory Pain - Drug Profile
- Product Description
- Mechanism Of Action
- Synthetic Peptides to Agonize AGTR2 for Kidney Fibrosis, Liver Fibrosis and Myocardial Fibrosis - Drug Profile
- Product Description
- Mechanism Of Action
- thalidomide - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- VP-01 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- VP-03 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- WXSH-0024 - Drug Profile
- Product Description
- Mechanism Of Action
- Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Dormant Products
- Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Discontinued Products
- Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Product Development Milestones
- Featured News & Press Releases
- Jun 28, 2022: Confo Therapeutics awarded EUR 1.7M VLAIO grant to expand application of ConfoBody drug discovery and development technology in rare diseases
- Jun 17, 2022: Vicore Pharma starts Phase I trial of angiotensin II type 2 receptor agonist
- Jun 03, 2022: Vicore amends primary endpoint to accelerate the Phase 3 trial in COVID-19 patients
- Mar 18, 2022: Vicore initiates human forearm blood flow study with C21
- Mar 10, 2022: Confo Therapeutics doses first subjects in phase 1 clinical trial of CFTX-1554 for the treatment of neuropathic pain
- Mar 10, 2022: Confo Therapeutics doses first subjects in phase 1 clinical trial of CFTX-1554 for the treatment of neuropathic pain
- Mar 09, 2022: Vicore strengthens rare lung disease pipeline with PAH indication
- Mar 04, 2022: Vicore to host R&D-Day
- Mar 04, 2022: Vicore to host R&D Day
- Feb 10, 2022: Vicore's AIR study interim analysis suggests that C21 improves lung function in IPF patients
- Dec 15, 2021: Confo Therapeutics expands patent estate for ConfoBody-based GPCR screening platform
- Nov 02, 2021: Vicore's C21 reduces long-term lung injury after COVID-19 in the ATTRACT Phase 2 extension study
- Oct 25, 2021: Vicore Pharma Holding: Lancet’s EClinicalMedicine publishes phase 2 data on C21 in COVID-19
- Sep 22, 2021: Vicore to host Key Opinion Leader webinar on C21 for the treatment of idiopathic pulmonary fibrosis (IPF)
- Sep 22, 2021: Vicore obtains SARS coronavirus patent for C21 in the USA
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
List of Tables
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Indication, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products under Investigation by Universities/Institutes, 2022
- Products under Investigation by Universities/Institutes, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Pipeline by Confo Therapeutics SA, 2022
- Pipeline by HK inno.N Corp, 2022
- Pipeline by MorphoSys AG, 2022
- Pipeline by Novopyxis Inc, 2022
- Pipeline by Shandong Danhong Pharmaceutical Co Ltd, 2022
- Pipeline by Vicore Pharma AB, 2022
- Dormant Projects, 2022
- Discontinued Products, 2022
List of Figures
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Top 10 Indications, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Confo Therapeutics SA
- HK inno.N Corp
- MorphoSys AG
- Novopyxis Inc
- Shandong Danhong Pharmaceutical Co Ltd
- Vicore Pharma AB
